Dr
Marco Traub PhD
Visiting
Scientist University of Kansas City, USA Research Director, Lugano, Switzerland
Research Director GeneMaLK SA, Switzerland.
EU-Commission Expert,No. EX2002B051556, Life Science, Brussels
Visiting Scientist, University of Kansas City.
RTD-SME Coordinator of the TESCT (TransEuropeanStemCellTherapy) Consortium
RTD-SME Coordinator and Technology Carrier of FP4 and SME-Coordinator
of FP5 EU-Commission and Swiss Governmental (Swiss Science Agency,
BBW) funded projects with
Rearch Awards from the EU-Commission and Swiss Government:
Qual Life FP4 "Development of Ultrasensitive Diagnostic Assays
for the Detection of Genetic Disorders, Infections and for Monitoring
the Therapeutic Success following Gene Therapy", BM-ST 9179, EU-Commission,
Brussels.
Qual Life FP5 “Establishment of novel targets for risk assessment
and monitoring of xenogeneic infections in the course of animal to
human transplantation”, QLK2-CT-2002-70785, EU-Commission, Brussels.
Swiss Science Agency (BBW) # 98.0264, Swiss Government, Bern. Swiss
Science Agency (BBW) # 01.0371, Swiss Government, Bern.
The main objectives of the research activities is a) development of stemcell
related tools b) development and marketing of porcine endogenous retrovirus
detection c) development of novel methods for the early detection of
genetically based diseases. Co-operations with the following research
institutions and companies: University of Texas, Medical Branch, USA;
University of Kansas City, Medical School.
2006 - Stem cell application, affordable medicine or
break down for the public health care system
Stem cell research has significant potential for
improving human health and quality of life by providing new routes
to drug discovery and by direct application in regenerative medicine.
To
bring stem cell technology to the clinic, further development and combination
of cutting edge postgenomically focused tools are necessary. These
platform methodologies revealing therapeutic potential and expression/epigenetic
profiling of cell differentiation with safety aspects in stem cells.
A prerequisite for rapid application is the availability of validated
postgenomically based tools. To monitor epigenetic programming including
pathways leading to specific epigenomic landscapes is of utmost importance
to understand stem cell differentiation and homeostasis. The involvement
of SMEs will have further socio economic impact worldwide. New concepts
have to be developed to make stem cell technology accessible and affordable
for the patients.
BSAAM's Anti Ageing
Conference London, 38 Regent on the River 
